ANDA 76831, held by Padagis US. Flavoxate Hydrochloride.
As of Nov 16, 2026, ANDA 76831 (Flavoxate Hydrochloride), held by Padagis US, was first approved by FDA on Dec 16, 2004, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Flavoxate HCl tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Flavoxate HCl tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 16, 2004 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Flavoxate Hydrochloride100MG · tablet;oral | Flavoxate Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters